Pharmacodynamics: Receptors, Dose-Response & Interactions

Pharmacodynamics is what a drug does to the body — how it binds receptors, produces effects, and interacts with other drugs. If pharmacokinetics is the body's effect on the drug, pharmacodynamics is the drug's effect on the body. Its core tools are receptors, dose–response curves, and the rules of drug interactions.

This matters because every prescription is a pharmacodynamics decision: which receptor to target, what dose gives effect without toxicity, and which combinations help or harm. The difference between a medicine and a poison is dose — and the dose–response curve maps that boundary.

Key Concepts

• Receptors: ion channels (fast), G-protein-coupled receptors (most drugs), enzyme-linked receptors, and nuclear receptors.
• Agonist vs antagonist: agonist binds and activates (morphine); antagonist binds but blocks (naloxone reverses morphine); partial agonist activates weakly and can block a full agonist (varenicline).
• Dose–response terms: EC50 — concentration for 50 percent of maximum effect (potency: lower EC50 = more potent); Emax — maximum achievable effect (efficacy); therapeutic index (TI) — TD50/ED50, the safety margin.
• Drug interactions: additive (1+1=2), synergistic (1+1>2, e.g., trimethoprim + sulfamethoxazole), antagonistic (one blocks another, e.g., naloxone vs opioids), potentiation (inactive drug boosts an active one).
• Tolerance and tachyphylaxis: tolerance needs higher doses over time (receptor downregulation); dependence brings withdrawal on stopping; tachyphylaxis is rapid tolerance within hours.

Formulas

• Therapeutic index: TI = TD50 / ED50 — TD50 is the dose toxic in 50 percent of the population, ED50 the dose effective in 50 percent; both in mg, so TI is unitless. Penicillin has a very high TI; warfarin a low one needing monitoring.
• Potency: drug A with EC50 1 mg vs drug B with EC50 10 mg — A is 10 times more potent (10/1). Potency says nothing about efficacy: a more potent drug is not "stronger" if its Emax is lower.
• Limits: these indices come from population curves; individuals vary with genetics, age and disease, so TI guides but never replaces monitoring.

Worked Example

Two painkillers: drug X has ED50 10 mg, TD50 100 mg; drug Y has ED50 5 mg, TD50 15 mg. Step 1: potency — Y's ED50 is half of X's, so Y is twice as potent; a smaller tablet works. Step 2: safety — TI of X = 100/10 = 10; TI of Y = 15/5 = 3. Step 3: X has the wider margin, so a dosing error with X is far less likely to reach toxicity. Step 4: Y is more potent but X is safer — for home use without monitoring, the higher TI usually wins. Potency tells you the dose size; the therapeutic index tells you the forgiveness.

Common Misconceptions

• "More potent means better." Potency only means a smaller dose is needed. A potent drug with low Emax or narrow TI can be worse than a safer alternative.
• "Two pills help twice as much." Curves flatten near Emax — doubling the dose past the plateau adds toxicity without benefit. This is how paracetamol overdoses destroy livers.
• "Natural products have no interactions." St. John's wort induces liver enzymes and can make transplant drugs, contraceptives and antidepressants fail.

Real-World Applications

• Prescribing: high-TI drugs (amoxicillin) for outpatient use; narrow-TI drugs (warfarin, lithium, digoxin) with blood-level monitoring.
• Overdose treatment: antagonists as antidotes — naloxone for opioids, flumazenil for benzodiazepines.
• Combination therapy: synergistic pairs achieve cures at lower, safer doses.
• Drug development: EC50, Emax and TI are measured before human trials; regulators demand a convincing safety margin.

Pharmacodynamics is receptors, curves and interactions: agonists switch receptors on, antagonists block them, EC50 measures potency, Emax measures efficacy, and the therapeutic index measures forgiveness.